Molecular oncogenesis of prostate adenocarcinoma: role of the human epidermal growth factor receptor 2 (HER-2/neu)
- PMID: 21302606
- DOI: 10.1177/030089161009600501
Molecular oncogenesis of prostate adenocarcinoma: role of the human epidermal growth factor receptor 2 (HER-2/neu)
Abstract
The potential mechanisms involving the genesis and growth of androgen-independent prostate cancer include super-expression of the androgen receptor (AR), in an attempt to compensate for the low androgenic plasma levels and mutations of this specific receptor, which could determine resistance to anti-androgenic therapy. However, most advanced prostate tumors have no mutations or amplifications of the AR, suggesting a potential role of non-androgenic growth factors, including epidermal growth factor (EGF), transforming growth factor alpha, insulin-like growth factor (IGF-1) and fibroblast growth factor. More specifically, these factors, and their receptors like EGFR (HER-1) and HER-2/neu, through paracrine and autocrine mechanisms, may contribute to the proliferation and growth of prostate cancer.
Similar articles
-
Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, and androgen receptor in phyllodes tumor of the prostate.Mod Pathol. 2007 Feb;20(2):175-82. doi: 10.1038/modpathol.3800724. Epub 2006 Dec 22. Mod Pathol. 2007. PMID: 17192792
-
Androgen-dependent regulation of Her-2/neu in prostate cancer cells.Cancer Res. 2006 Jun 1;66(11):5723-8. doi: 10.1158/0008-5472.CAN-05-3928. Cancer Res. 2006. PMID: 16740710
-
Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.BJU Int. 2006 Jan;97(1):170-8. doi: 10.1111/j.1464-410X.2006.05857.x. BJU Int. 2006. PMID: 16336351
-
HER-2/neu receptor in prostate cancer development and progression to androgen independence.Tumori. 2004 Mar-Apr;90(2):163-70. doi: 10.1177/030089160409000201. Tumori. 2004. PMID: 15237576 Review.
-
Molecular mechanisms in hormone-resistant prostate cancer.Rev Med Chir Soc Med Nat Iasi. 2005 Jul-Sep;109(3):577-83. Rev Med Chir Soc Med Nat Iasi. 2005. PMID: 16607754 Review.
Cited by
-
Molecular and cellular mechanisms of castration resistant prostate cancer.Oncol Lett. 2018 May;15(5):6063-6076. doi: 10.3892/ol.2018.8123. Epub 2018 Feb 27. Oncol Lett. 2018. PMID: 29616091 Free PMC article. Review.
-
Natural Product-Based Studies for the Management of Castration-Resistant Prostate Cancer: Computational to Clinical Studies.Front Pharmacol. 2021 Oct 19;12:732266. doi: 10.3389/fphar.2021.732266. eCollection 2021. Front Pharmacol. 2021. PMID: 34737700 Free PMC article. Review.
-
Cardiometabolic complications after androgen deprivation therapy in a man with prostate cancer: effects of 3 years intermittent testosterone supplementation.Front Endocrinol (Lausanne). 2012 Feb 16;3:17. doi: 10.3389/fendo.2012.00017. eCollection 2012. Front Endocrinol (Lausanne). 2012. PMID: 22645517 Free PMC article.
-
Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets.J Steroid Biochem Mol Biol. 2017 Feb;166:16-27. doi: 10.1016/j.jsbmb.2016.07.006. Epub 2016 Jul 30. J Steroid Biochem Mol Biol. 2017. PMID: 27481707 Free PMC article. Review.
-
Genetic variation: effect on prostate cancer.Biochim Biophys Acta. 2014 Dec;1846(2):446-56. doi: 10.1016/j.bbcan.2014.08.007. Epub 2014 Sep 6. Biochim Biophys Acta. 2014. PMID: 25199985 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous